Article Text

PDF
Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration
  1. M Bolz1,
  2. C Simader1,
  3. M Ritter1,
  4. C Ahlers1,
  5. T Benesch2,
  6. C Prünte1,
  7. U Schmidt-Erfurth1
  1. 1Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  2. 2Core Unit of Medical Statistics and Informatics, Section of Medical Statistics, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Dr U Schmidt-Erfurth, Department of Ophthalmology, Medical University of Vienna, Wahringer Gurtel 18–20, 1090 Vienna, Austria; ursula.schmidt-erfurth{at}meduniwien.ac.at

Abstract

Aim To quantify and correlate the morphological and functional effects of the recommended loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration (AMD).

Methods In a prospective, interventional clinical trial, 29 consecutive patients (29 eyes) with choroidal neovascularisation secondary to AMD received three initial monthly intravitreal injections of ranibizumab. During this loading regimen, best corrected visual acuity (BCVA) and microperimetry (MP) testing, as well as optical coherence tomography and fluorescein angiography (FA), were performed using a standardised protocol and the results correlated.

Results Significant morphological and functional therapeutic effects were observed as early as 1 week following the first treatment. Throughout the loading-dose period, central retinal thickness, including intraretinal cysts and subretinal fluid, decreased fast and significantly (p<0.01); pigment epithelial detachment resolved less rapidly. The mean leakage area by FA decreased (p<0.01) and retinal function (BCVA and MP) increased significantly (both p<0.01). However, the change in morphology and function was only significant between baseline and week 1. There was no significant additional morphological or functional benefit following the second and third injection.

Conclusion The initial administration of intravitreal ranibizumab in neovascular AMD induced a significant effect on intra- and subretinal fluid and visual function; subsequent injections had a less pronounced effect. It remains to be determined whether this loading regimen should be mandatory in all patients or if a single dose regimen would lead to a comparable functional and morphological retinal improvement.

Statistics from Altmetric.com

Footnotes

  • Funding Novartis Pharma, Basel, Switzerland.

  • Competing interests None.

  • Ethics approval All the research and measurements adhered to the tenets of the Helsinki agreement. The study was approved by the local ethics committee.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.